{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:46:02Z","timestamp":1792590362874,"version":"4.5.0"},"reference-count":21,"publisher":"MyJove Corporation","issue":"229","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/69797","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:02:17Z","timestamp":1772841737000},"source":"Crossref","is-referenced-by-count":0,"title":["The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage"],"prefix":"10.3791","author":[{"given":"Fang-Tong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai-Shuai","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Ling","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Feng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Bai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","type":"journal-article","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J., Bloomfield, C. D. Acute myeloid leukemia. N Engl J Med. 373 (12), 1136-1152 (2015).","journal-title":"N Engl J Med"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V89.11.4226","type":"journal-article","article-title":"Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose","volume":"89","author":"Sierra","year":"1997","unstructured":"Sierra, J. et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 89 (11), 4226-4235 (1997).","journal-title":"Blood"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11899-011-0101-2","type":"journal-article","article-title":"Management of refractory acute myeloid leukemia: Re-induction therapy or straight to transplantation","volume":"7","author":"Feldman","year":"2012","unstructured":"Feldman, E. J. Gergis, U. Management of refractory acute myeloid leukemia: Re-induction therapy or straight to transplantation? Curr Hematol Malig Rep. 7 (1), 74-77 (2012).","journal-title":"Curr Hematol Malig Rep"},{"issue":"33","key":"ref4","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","type":"journal-article","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","unstructured":"Kadia, T. M. et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 40 (33), 3848-3857 (2022).","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"ref5","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2022-168054","type":"journal-article","article-title":"cladribine plus low-dose cytarabine achieved high remission in patients with relapse\/refractory acute leukemia: Preliminary results of a phase II study","volume":"140","author":"Li","year":"2022","unstructured":"Li, Y. et al. Venetoclax, cladribine plus low-dose cytarabine achieved high remission in patients with relapse\/refractory acute leukemia: Preliminary results of a phase II study. Blood. 140 (Supplement 1), 3212-3213 (2022).","journal-title":"Blood"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","type":"journal-article","article-title":"DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","unstructured":"Roos, W. P. Kaina, B. DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 332 (2), 237-248 (2013).","journal-title":"Cancer Lett"},{"issue":"17","key":"ref7","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1016\/j.febslet.2010.05.021","type":"journal-article","article-title":"Focus on histone variant h2ax: To be or not to be","volume":"584","author":"Yuan","year":"2010","unstructured":"Yuan, J., Adamski, R., Chen, J. Focus on histone variant h2ax: To be or not to be. FEBS Lett. 584 (17), 3717-3724 (2010).","journal-title":"FEBS Lett"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4161\/cbt.10.11.13556","type":"journal-article","article-title":"The ubiquitin-proteasome pathway plays essential roles in atra-induced leukemia cells G0\/G1 phase arrest and transition into granulocytic differentiation","volume":"10","author":"Fang","year":"2010","unstructured":"Fang, Y. et al. The ubiquitin-proteasome pathway plays essential roles in atra-induced leukemia cells G0\/G1 phase arrest and transition into granulocytic differentiation. Cancer Biol Ther. 10 (11), 1157-1167 (2010).","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tcb.2011.01.004","type":"journal-article","article-title":"Regulation of cell differentiation by the DNA damage response","volume":"21","author":"Sherman","year":"2011","unstructured":"Sherman, M. H., Bassing, C. H., Teitell, M. A. Regulation of cell differentiation by the DNA damage response. Trends Cell Biol. 21 (5), 312-319 (2011).","journal-title":"Trends Cell Biol"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0167-5699(93)90212-4","type":"journal-article","article-title":"Cd14: Cell surface receptor and differentiation marker","volume":"14","author":"Ziegler-Heitbrock","year":"1993","unstructured":"Ziegler-Heitbrock, H. W. Ulevitch, R. J. Cd14: Cell surface receptor and differentiation marker. Immunol Today. 14 (3), 121-125 (1993).","journal-title":"Immunol Today"},{"issue":"Supplement 1","key":"ref11","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood-2023-185185","type":"journal-article","article-title":"Venetoclax + cladribine + low-dose cytarabine in acute myeloid leukemia relapsed or refractory to venetoclax + hypomethylating agent","volume":"142","author":"Steinauer","year":"2023","unstructured":"Steinauer, N. et al. Venetoclax + cladribine + low-dose cytarabine in acute myeloid leukemia relapsed or refractory to venetoclax + hypomethylating agent. Blood. 142 (Supplement 1), 2853-2853 (2023).","journal-title":"Blood"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm3999","type":"journal-article","article-title":"Live to die another way: Modes of programmed cell death and the signals emanating from dying cells","volume":"16","author":"Fuchs","year":"2015","unstructured":"Fuchs, Y., Steller, H. Live to die another way: Modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol. 16 (6), 329-344 (2015).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","type":"journal-article","article-title":"The role of Bcl-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","unstructured":"Qian, S. et al. The role of Bcl-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 12, 985363 (2022).","journal-title":"Front Oncol"},{"issue":"16","key":"ref14","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/blood-2010-02-246140","type":"journal-article","article-title":"Beyond hairy cell: The activity of cladribine in other hematologic malignancies","volume":"116","author":"Sigal","year":"2010","unstructured":"Sigal, D. S., Miller, H. J., Schram, E. D., Saven, A. Beyond hairy cell: The activity of cladribine in other hematologic malignancies. Blood. 116 (16), 2884-2896 (2010).","journal-title":"Blood"},{"issue":"20","key":"ref15","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1158\/0008-5472.CAN-16-1248","type":"journal-article","article-title":"Finally, an apoptosis-targeting therapeutic for cancer","volume":"76","author":"Croce","year":"2016","unstructured":"Croce, C. M. Reed, J. C. Finally, an apoptosis-targeting therapeutic for cancer. Cancer Res. 76 (20), 5914-5920 (2016).","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"115494","DOI":"10.1016\/j.bcp.2023.115494","type":"journal-article","article-title":"Cytarabine-induced destabilization of mcl1 mRNA and protein triggers apoptosis in leukemia cells","volume":"211","author":"Chiou","year":"2023","unstructured":"Chiou, J. T., Hsu, C. C., Hong, Y. C., Lee, Y. C., Chang, L. S. Cytarabine-induced destabilization of mcl1 mRNA and protein triggers apoptosis in leukemia cells. Biochem Pharmacol. 211, 115494 (2023).","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","type":"journal-article","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","unstructured":"Pei, S. et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 13 (9), 2032-2049 (2023).","journal-title":"Cancer Discov"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","type":"journal-article","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions","volume":"87","author":"Gandhi","year":"1996","unstructured":"Gandhi, V., Estey, E., Keating, M. J., Chucrallah, A., Plunkett, W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 87 (1), 256-264 (1996).","journal-title":"Blood"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1186\/s12885-020-07701-8","type":"journal-article","article-title":"Radotinib enhances cytarabine (ara-c)-induced acute myeloid leukemia cell death","volume":"20","author":"Heo","year":"2020","unstructured":"Heo, S. K. et al. Radotinib enhances cytarabine (ara-c)-induced acute myeloid leukemia cell death. BMC Cancer. 20 (1), 1193 (2020).","journal-title":"BMC Cancer"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"11344","DOI":"10.1038\/s41598-022-15520-z","type":"journal-article","article-title":"Cytarabine-induced differentiation of AML cells depends on CHK1 activation and shares the mechanism with inhibitors of dHODH and pyrimidine synthesis","volume":"12","author":"Tomic","year":"2022","unstructured":"Tomic, B. et al. Cytarabine-induced differentiation of AML cells depends on CHK1 activation and shares the mechanism with inhibitors of dHODH and pyrimidine synthesis. Sci Rep. 12 (1), 11344 (2022).","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2014.10.064","type":"journal-article","article-title":"Rosmarinic acid potentiates atra-induced macrophage differentiation in acute promyelocytic leukemia NB4 cells","volume":"747","author":"Heo","year":"2015","unstructured":"Heo, S. K. et al. Rosmarinic acid potentiates atra-induced macrophage differentiation in acute promyelocytic leukemia NB4 cells. Eur J Pharmacol. 747, 36-44 (2015).","journal-title":"Eur J Pharmacol"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/69797\/the-regimen-cladribine-cytarabine-venetoclax-cav-induces-apoptosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:18:47Z","timestamp":1792588727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/69797\/the-regimen-cladribine-cytarabine-venetoclax-cav-induces-apoptosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":21,"journal-issue":{"issue":"229","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/69797","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}